{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:15:03Z","timestamp":1769170503126,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T00:00:00Z","timestamp":1487376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T00:00:00Z","timestamp":1487376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0438"],"award-info":[{"award-number":["W81XWH-16-1-0438"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-IRG-03-16"],"award-info":[{"award-number":["SU2C-AACR-IRG-03-16"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00262-017-1958-2","type":"journal-article","created":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T07:03:51Z","timestamp":1487401431000},"page":"969-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer"],"prefix":"10.1007","volume":"66","author":[{"given":"Chang-Suk","family":"Chae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Teran-Cabanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4267-4893","authenticated-orcid":false,"given":"Juan R.","family":"Cubillos-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,18]]},"reference":[{"issue":"1","key":"1958_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7\u201330","journal-title":"CA Cancer J Clin"},{"key":"1958_CR2","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA et al (2016) Ovarian cancer. Nat Rev Dis Primers 2:16061","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1958_CR3","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","volume":"5","author":"GH Giornelli","year":"2016","unstructured":"Giornelli GH (2016) Management of relapsed ovarian cancer: a review. SpringerPlus 5(1):1197","journal-title":"SpringerPlus"},{"issue":"3","key":"1958_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203\u2013213","journal-title":"N Engl J Med"},{"issue":"15","key":"1958_CR5","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1158\/0008-5472.CAN-08-4329","volume":"69","author":"Y Nesbeth","year":"2009","unstructured":"Nesbeth Y et al (2009) CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 69(15):6331\u20136338","journal-title":"Cancer Res"},{"issue":"10","key":"1958_CR6","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.4049\/jimmunol.0903247","volume":"184","author":"YC Nesbeth","year":"2010","unstructured":"Nesbeth YC et al (2010) CD4 + T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol 184(10):5654\u20135662","journal-title":"J Immunol"},{"issue":"9","key":"1958_CR7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/nm1097","volume":"10","author":"JR Conejo-Garcia","year":"2004","unstructured":"Conejo-Garcia JR et al (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10(9):950\u2013958","journal-title":"Nat Med"},{"issue":"6","key":"1958_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1600-0897.2005.00330.x","volume":"54","author":"B Barnett","year":"2005","unstructured":"Barnett B et al (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54(6):369\u2013377","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"1958_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel TJ et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9(5):562\u2013567","journal-title":"Nat Med"},{"issue":"18","key":"1958_CR10","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.1158\/0008-5472.CAN-08-1167","volume":"68","author":"E Huarte","year":"2008","unstructured":"Huarte E et al (2008) Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 68(18):7684\u20137691","journal-title":"Cancer Res"},{"issue":"8","key":"1958_CR11","first-page":"2231","volume":"119","author":"JR Cubillos-Ruiz","year":"2009","unstructured":"Cubillos-Ruiz JR et al (2009) Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119(8):2231\u20132244","journal-title":"J Clin Invest"},{"issue":"4","key":"1958_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1958_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205\u2013214","journal-title":"Cell"},{"issue":"5796","key":"1958_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126\u2013129","journal-title":"Science"},{"issue":"5594","key":"1958_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850\u2013854","journal-title":"Science"},{"issue":"34","key":"1958_CR16","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J et al (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33(34):4015\u20134022","journal-title":"J Clin Oncol"},{"issue":"20 Pt 1","key":"1958_CR17","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106\u20136115","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1958_CR18","doi-asserted-by":"publisher","first-page":"e22664","DOI":"10.4161\/onci.22664","volume":"2","author":"LE Kandalaft","year":"2013","unstructured":"Kandalaft LE et al (2013) Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2(1):e22664","journal-title":"Oncoimmunology"},{"issue":"5966","key":"1958_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1178331","volume":"327","author":"F Geissmann","year":"2010","unstructured":"Geissmann F et al (2010) Development of monocytes, macrophages, and dendritic cells. Science 327(5966):656\u2013661","journal-title":"Science"},{"issue":"5","key":"1958_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.immuni.2014.04.016","volume":"40","author":"A Mildner","year":"2014","unstructured":"Mildner A, Jung S (2014) Development and function of dendritic cell subsets. Immunity 40(5):642\u2013656","journal-title":"Immunity"},{"issue":"13","key":"1958_CR21","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1182\/blood-2011-12-380113","volume":"119","author":"H Takizawa","year":"2012","unstructured":"Takizawa H, Boettcher S, Manz MG (2012) Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood 119(13):2991\u20133002","journal-title":"Blood"},{"issue":"4","key":"1958_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253\u2013268","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"1958_CR23","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499\u20134506","journal-title":"J Immunol"},{"key":"1958_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pharmthera.2016.04.003","volume":"164","author":"JR Conejo-Garcia","year":"2016","unstructured":"Conejo-Garcia JR, Rutkowski MR, Cubillos-Ruiz JR (2016) State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther 164:97\u2013104","journal-title":"Pharmacol Ther"},{"issue":"18","key":"1958_CR25","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1158\/0008-5472.CAN-09-0835","volume":"69","author":"UK Scarlett","year":"2009","unstructured":"Scarlett UK et al (2009) In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 69(18):7329\u20137337","journal-title":"Cancer Res"},{"issue":"3","key":"1958_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1084\/jem.20111413","volume":"209","author":"UK Scarlett","year":"2012","unstructured":"Scarlett UK et al (2012) Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209(3):495\u2013506","journal-title":"J Exp Med"},{"issue":"3","key":"1958_CR27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","volume":"158","author":"M Munder","year":"2009","unstructured":"Munder M, Arginase (2009) an emerging key player in the mammalian immune system. Br J Pharmacol 158(3):638\u2013651","journal-title":"Br J Pharmacol"},{"issue":"5","key":"1958_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.18632\/oncotarget.165","volume":"1","author":"JR Cubillos-Ruiz","year":"2010","unstructured":"Cubillos-Ruiz JR et al (2010) CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget 1(5):329\u2013338","journal-title":"Oncotarget"},{"issue":"12","key":"1958_CR29","doi-asserted-by":"publisher","first-page":"15385","DOI":"10.1007\/s13277-016-5436-9","volume":"37","author":"HT Liu","year":"2016","unstructured":"Liu HT, Gao P (2016) The roles of microRNAs related with progression and metastasis in human cancers. Tumor Biol 37(12):15383\u201315397. doi:\n                    10.1007\/s13277-016-5436-9","journal-title":"Tumor Biol"},{"issue":"5824","key":"1958_CR30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1126\/science.1139253","volume":"316","author":"A Rodriguez","year":"2007","unstructured":"Rodriguez A et al (2007) Requirement of bic\/microRNA-155 for normal immune function. Science 316(5824):608\u2013611","journal-title":"Science"},{"issue":"7","key":"1958_CR31","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-11-3160","volume":"72","author":"JR Cubillos-Ruiz","year":"2012","unstructured":"Cubillos-Ruiz JR et al (2012) Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 72(7):1683\u20131693","journal-title":"Cancer Res"},{"issue":"2","key":"1958_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2012-08-449306","volume":"122","author":"E Zonari","year":"2013","unstructured":"Zonari E et al (2013) A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood 122(2):243\u2013252","journal-title":"Blood"},{"issue":"7","key":"1958_CR33","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.celrep.2016.01.056","volume":"14","author":"AJ Tesone","year":"2016","unstructured":"Tesone AJ et al (2016) Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells. Cell Rep 14(7):1774\u20131786","journal-title":"Cell Rep"},{"issue":"7","key":"1958_CR34","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz JR et al (2015) ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161(7):1527\u20131538","journal-title":"Cell"},{"issue":"9","key":"1958_CR35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrd3976","volume":"12","author":"C Hetz","year":"2013","unstructured":"Hetz C, Chevet E, Harding HP (2013) Targeting the unfolded protein response in disease. Nat Rev Drug Discov 12(9):703\u2013719","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1958_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","volume":"107","author":"H Yoshida","year":"2001","unstructured":"Yoshida H et al (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107(7):881\u2013891","journal-title":"Cell"},{"issue":"21","key":"1958_CR37","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1128\/MCB.23.21.7448-7459.2003","volume":"23","author":"AH Lee","year":"2003","unstructured":"Lee AH, Iwakoshi NN, Glimcher LH (2003) XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 23(21):7448\u20137459","journal-title":"Mol Cell Biol"},{"issue":"6","key":"1958_CR38","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1172\/JCI73448","volume":"124","author":"CH Tang","year":"2014","unstructured":"Tang CH et al (2014) Inhibition of ER stress-associated IRE-1\/XBP-1 pathway reduces leukemic cell survival. J Clin Invest 124(6):2585\u20132598","journal-title":"J Clin Invest"},{"issue":"7494","key":"1958_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature13119","volume":"508","author":"X Chen","year":"2014","unstructured":"Chen X et al (2014) XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 508(7494):103\u2013107","journal-title":"Nature"},{"issue":"35","key":"1958_CR40","doi-asserted-by":"publisher","first-page":"15553","DOI":"10.1073\/pnas.0914072107","volume":"107","author":"G Auf","year":"2010","unstructured":"Auf G et al (2010) Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci USA 107(35):15553\u201315558","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1958_CR41","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/bjc.2013.66","volume":"108","author":"LE Dalton","year":"2013","unstructured":"Dalton LE et al (2013) The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer 108(6):1340\u20131347","journal-title":"Br J Cancer"},{"issue":"1","key":"1958_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ijc.23479","volume":"123","author":"MP Davies","year":"2008","unstructured":"Davies MP et al (2008) Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer 123(1):85\u201388","journal-title":"Int J Cancer"},{"issue":"3","key":"1958_CR43","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ygyno.2012.11.024","volume":"128","author":"K Matsuo","year":"2013","unstructured":"Matsuo K et al (2013) The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival. Gynecol Oncol 128(3):552\u2013559","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1958_CR44","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber DL et al (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 16(8):880\u2013886","journal-title":"Nat Med"},{"issue":"2","key":"1958_CR45","doi-asserted-by":"publisher","first-page":"aaf8943","DOI":"10.1126\/sciimmunol.aaf8943","volume":"1","author":"T Condamine","year":"2016","unstructured":"Condamine T et al (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 1(2):aaf8943","journal-title":"Sci Immunol"},{"issue":"6684","key":"1958_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","volume":"393","author":"SP Schoenberger","year":"1998","unstructured":"Schoenberger SP et al (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions. Nature 393(6684):480\u2013483","journal-title":"Nature"},{"issue":"6684","key":"1958_CR47","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/30996","volume":"393","author":"SR Bennett","year":"1998","unstructured":"Bennett SR et al (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684):478\u2013480","journal-title":"Nature"},{"issue":"6024","key":"1958_CR48","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL et al (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612\u20131616","journal-title":"Science"},{"issue":"5","key":"1958_CR49","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00262-013-1427-5","volume":"62","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH et al (2013) CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 62(5):949\u2013954","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1958_CR50","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2016.08.004","volume":"30","author":"I Marigo","year":"2016","unstructured":"Marigo I et al (2016) T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30(3):377\u2013390","journal-title":"Cancer Cell"},{"issue":"22","key":"1958_CR51","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","volume":"19","author":"GL Beatty","year":"2013","unstructured":"Beatty GL et al (2013) A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19(22):6286\u20136295","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1958_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/neuonc\/noq071","volume":"12","author":"MR Rosenfeld","year":"2010","unstructured":"Rosenfeld MR et al (2010) A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 12(10):1071\u20131077","journal-title":"Neuro Oncol"},{"issue":"17","key":"1958_CR53","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1007\/s00018-009-0053-z","volume":"66","author":"H Hillaireau","year":"2009","unstructured":"Hillaireau H, Couvreur P (2009) Nanocarriers\u2019 entry into the cell: relevance to drug delivery. CMLS Cell Mol Life Sci 66(17):2873\u20132896","journal-title":"CMLS Cell Mol Life Sci"},{"issue":"8","key":"1958_CR54","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2217\/fon.09.101","volume":"5","author":"JR Cubillos-Ruiz","year":"2009","unstructured":"Cubillos-Ruiz JR, Fiering S, Conejo-Garcia JR (2009) Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol 5(8):1189\u20131192","journal-title":"Future Oncol"},{"key":"1958_CR55","doi-asserted-by":"crossref","unstructured":"Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 31(7):397\u2013405","DOI":"10.1016\/j.tibtech.2013.04.004"},{"issue":"2","key":"1958_CR56","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt RJ et al (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2):440\u2013455","journal-title":"Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-1958-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-1958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-1958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:31:26Z","timestamp":1589628686000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-1958-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,18]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1958"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-1958-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,18]]},"assertion":[{"value":"3 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Juan R. Cubillos-Ruiz is co-founder and scientific advisor for Quentis Therapeutics, Inc. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}